Page 78 - Memora anual Fundación CIEN 2017
P. 78

The type of primary aliquots that are obtained in        It is also important to emphasize that the samples ob-
duplicate are the following:                             tained from Vallecas Project volunteers aged bet-
                                                         ween 70 and 85 years (at the baseline evaluation)
   • Whole blood (ST, for its acronym in Spanish)        that include a comprehensive assessment of cogni-
   • Platelets-rich plasma (PRP)                         tive, sociological and neuroimaging state are opti-
   • Platelets-free plasma (PFP)                         mal for its use as a control population in various
   • Buffy Coat (BC)                                     projects related to neurodegenerative diseases, es-
   • Red blood cells (RBC)                               pecially Alzheimer's disease. The monitoring for a pe-
   • Serum (Suero, in Spanish)                           riod of 5 years will allow us to detect early, even
   • Mononucleate leukocytes (LM, for its                before clinical symptoms manifestation, susceptibi-
                                                         lity factors and biomarkers associated with Alzhei-
       acronym in Spanish)                               mer's disease.

Genomic DNA was extracted from whole blood of            Research Program of the Queen Sofia Foundation
all participants who have signed informed consent        Alzheimer Center, This program focuses on regular
to it and the APOE gene, an important marker of ge-      and protocol-based monitoring of a cohort of CAFRS
netic risk for Alzheimer's disease, was analyzed. The    patients with dementia, ether as residents at the
comparison of the frequency of APOE allele 4 ca-        Center or attendants at the Day Center, with the
rriers between CAFRS patients and Vallecas Project       main objective of investigating the final stages of Alz-
volunteers confirms the risk to suffer from Alzheimer's  heimer's disease. A family member or guardian re-
disease with an OR = 3.53 (p <0.001). In addition, in    cruits patients into the monitoring program after
order to define different subpopulations of genetic      signing an Informed Consent. The Alzheimer Project
risk, other possible genetic susceptibility genes have   program consists of i) a biannual clinical and neu-
also been analyzed in a subset of participants (see fi-
gure).

               The Vallecas Project activity in figures

Evaluation     1º 2º 3º                                  4º 5º  6º           TOTAL

Total samples  1.169                     767  755        648    384 0        3.723

2017 samples   0 00                                      51 234 249          534

Total          1.169 767 755 699                                618 249      4.257

Nº Aliquotes   16.366                    10.738 10.570   9.786  8.652 3.486  59.598

CIEN Foundation Annual Report 2017 / 78
   73   74   75   76   77   78   79   80   81   82   83